Has Chris Derk, MD received payments from drug or device companies?

Yes. Drug and device makers reported $66,094 in general payments to Chris Derk, MD across 43 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chris Derk, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chris Derk, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chris Derk, MD

Rheumatology · Philadelphia, PANPI 1609899210

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $63,239 of the $66,094 with a category attached, or 95.7%. 10 manufacturers reported payments, led by Astrazeneca UK Limited at 53.6% of the total. 2025 is the largest year on record at $33,252, 3.9 times the $8,449 reported in 2019. Among rheumatology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$66,094in general payments, 2019–2025

Across 43 payments — averaging $1537.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca UK Limited$35K
Boehringer Ingelheim International GmbH$10K
Boehringer Ingelheim$9K
Novartis$5K
Ortho Dermatologics, A Division Of Bausch Health US, LLC$4K
CSL Behring$2K
plus $2K from 4 others

$176,432in research payments, 2019–2025

Across 41 payments — averaging $4303.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$149K
CSL Behring$27K

What the payments were for

Consulting fees$63,23996%
Travel & lodging$1,9783%
Food & beverage$8771%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca UK Limited	9	$35,400
Boehringer Ingelheim International GmbH	5	$9,729
Boehringer Ingelheim	4	$8,777
Novartis	4	$5,184
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$3,600
CSL Behring	15	$1,852
Vertex	2	$885
ZOLL Medical Corporation	1	$508
E.r. Squibb & Sons, L.L.C.	1	$119
GSK	1	$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SAPHNELO$28,400
ILARIS$5,184
Privigen$1,389
Defibrillator$508
COBENFY$119

How this compares

$66,094 in reported general payments places this provider in the 90th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$58,708

Medicare patients

224

Services billed

677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
HumiraAdalimumab	24	$238,245
KineretAnakinra	24	$137,470
Humira PenAdalimumab	16	$119,909
Humira(Cf)Adalimumab	14	$101,040
EnbrelEtanercept	12	$88,052
RinvoqUpadacitinib	12	$75,296
OtezlaApremilast	12	$57,890
Hydroxychloroquine Sulfate	313	$9,215
Sildenafil Citrate	15	$5,670
Mycophenolate Mofetil	40	$4,424
Lidocaine	14	$2,823
MethotrexateMethotrexate Sodium	98	$1,729
Prednisone	233	$1,645
Leflunomide	22	$1,625
Celecoxib	57	$1,470

Paid to pharmacies, not to this prescriber.

Other rheumatology in Philadelphia

Alan EpsteinPhiladelphia$1.2M
Alexis Ogdie-BeattyPhiladelphia$433K
Nora SandorfiPhiladelphia$52K
Lawrence BrentPhiladelphia$22K
Ethan CraigPhiladelphia$21K
Monica LuchiPhiladelphia$20K
Lawrence LeventhalHuntingdon Valley$1.1M
Alan KivitzDuncansville$936K
Paula HerringNewtown Square$920K
Rohit AggarwalPittsburgh$810K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →